Blake Lapthorn's Biotechnology and
Pharmaceuticals team cover advice, assistance and action on
all of the following:
licensing and joint ventures
- Licensing structures for bioinformatics products
- Licensing cell lines and other biotech materials
- Reach through licensing
- Collaborative joint ventures and other partnering structures
with mid and big pharmas
- Developments agreements for medical devices
- Co-marketing agreements
- Strategic development and manufacturing alliances in
diagnostics
funding issues
- Angel and VC funding rounds
- Initial public offerings
- Debt financing
international issues
- Many biotechnology and pharmaceutical companies, even at the
earliest stages of growth, may find themselves dealing with
international agreements and intellectual property (IP) issues. The
firm is a member of TAGLaw®, a worldwide network of quality
law firms selected for their ability to deliver exceptional legal
services for all aspects of corporate and commercial work, both
contentious and non-contentious. TAGLaw has associated firms in
over 80 jurisdictions around the world.
International services we can provide:
- parallel importations of pharmaceutical products
- advising on the effects of the UK and EU competition law on
licenses of worldwide or EMEA rights, even where the entities
involved are not based in the EU
royalties and intellectual property
- Royalty stacking issues
- Patent pooling
- European database rights
combining business and academia
- UK university spin-out companies support advisers who have real
experience of helping to accelerate the development of hi-tech
businesses. We offer business-orientated advice to enable you to
concentrate on commercialising the technology.
